Auris O Huen
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Auris O Huen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:19 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04234048 · Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaSciTech Development, Inc. · recruiting · T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma · principal investigator
- Ph2NCT01352520 · SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)M.D. Anderson Cancer Center · active not recruiting · CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Lymphomatoid Papulosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:19 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- 99 citationsRCR 21.9
- Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.JAMA Dermatol · 201726 citationsRCR 1.2